key: cord-0778699-emct8b23 authors: McBane, Robert D. title: Thromboembolism and the Pandemic date: 2020-11-03 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.09.543 sha: 4e2c7fd75b1cfa9caaa8455df85e0fc4f8e3af67 doc_id: 778699 cord_uid: emct8b23 [Figure: see text] Thromboembolism and the Pandemic* ISTH interim guidance on recognition and management of coagulopathy in COVID-19 for the Global COVID-19 Thrombosis Collaborative Group. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum Registry of arterial and venous thromboembolic complications in patients with COVID-19 Postdischarge venous thromboembolism following hospital admission with COVID-19 Dalteparin versus unfractionated heparin in critically ill patients Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors for the Prophylaxis for Thromboembolism in Critical Care Trial Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study The cumulative venous thromboembolism incidence and risk factors in intensive care patient is receiving guideline recommended thromboprophylaxis VTE incidence and risk factors in patients with severe sepsis and septic shock Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients Rivaroxaban for thromboprophylaxis in acutely ill medical patients Extended thromboprophylaxis with betrixaban in acutely ill medical patients for the Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in High risk for thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study